16 Aug 2022 , 10:59 AM
The company stated that Vasopressin Injection USP, 20 Units/mL Multiple-Dose Vials, are to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vasostrict Injection, 20 units/mL of Par Sterile Products, LLC (Par).
The company is planning to launch the product immediately.
As per the IQVIA data, the product has an estimated market size of around US$ 606 million for the twelve months ended June 2022.
This is the 146 ANDA (including ten tentative approvals) received by Eugia Pharma Speciality Group (EPSG) facilities, which manufacture both oral and sterile specialty products.
Vasopressin USP Injection is prescribed to treat Cardiovascular agent: vasoconstrictor. It is indicated to raise blood pressure in adults suffering from vasodilatory shock (for example, post-cardiotomy or sepsis).
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.